Jaguar health secures additional capital through sale of royalty rights related to future crofelemer and lechlemer revenue stream

Transaction proceeds will be allocated to support the company's ongoing ontarget pivotal phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapy san francisco, ca / accesswire / august 25, 2022 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company"), today announced that the company has entered into a royalty interest purchase agreement (the "agreement") with utah-based streeterville capital, llc ("streeterville"). under the agreement, jaguar will immediately receive $4.0 million (the "royalty purchase price") in connection with the sale of a royalty interest to streeterville entitling streeterville to receive 3-fold of the royalty purchase price from future royalties on sales of crofelemer and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors, excluding any fees due to jaguar from its crofelemer license for the european territory to napo therapeutics, s.p.a.
JAGX Ratings Summary
JAGX Quant Ranking